CTC Clinical Trial Consultants AB

Rising interest in CRISPR treatments

Treatments using CRISPR technology are emerging as one of the hottest medical trends in the United States – and the FDA is doing its best to promote the development.

Bico säljer bolag inom in vitro-testning och digital patologi

Bioteknikbolaget Bico avyttrar Mattek och Visikol, som integrerades i Mattek operationellt förra året, till Sartorius Lab. Köpeskillingen är på 80 miljoner doll...

Studienamn med attityd – viktigare än man kan tro

Ironman, T-rex, Star-trec. Popcorn, Proper, Scout. Nej, det handlar varken om fantasyfilmer eller hundnamn. Utan om benämningar på pågående cancerstudier i Sverige.

The First Multi-Technology System from ZEISS

Microscope and measuring machine in one.

The new Swedish life science strategy – “It will consolidate Sweden as a leader”

Clinical trials and precision health are emphasised as key areas in the new national life science strategy.

Pila Pharma tar in 20 miljoner kronor – inleder ”dedikerat fetmaspår”

Malmöbolaget Pila Pharma utvecklar ett nytt, oralt läkemedel för behandling av typ 2-diabetes. Ett nytt kapitaltillskott ska användas för att initiera studier o...

To build trust, one must be able to say “I don’t know” – whether human or AI

Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.

He takes over the chairmanship of Karolinska Development

Ben Toogood is appointed as the new chairman of Karolinska Developments.

Metabolon

Cellevate stärker ledningen – utnämner CTO

Biotechbolaget Cellevate utnämner Christel Fenge till Chief Technology Officer (CTO).

Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.

Lucy Robertshaw: Artificial intelligence – is this really going to transform a patient’s life?

In a column Lucy Robertshaw reflects on how AI and new regulations will affect healthcare, innovation and the lives of future patients.

Xbrane enters licensing agreement with Indian generics giant

Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.

”Forskning är alltid en massa misslyckanden och några få succéer”

Genterapier öppnar fantastiska möjligheter, men är också extremt dyra att producera. Genenova ska ändra på det – och göra läkemedlen tillgängliga för fler. ”Vår...

Orbán's extended arm becomes health commissioner in the EU

Hungarian Olivér Várhelyi may soon become the most influential official for the healthcare and pharmaceutical industry in the EU. Várhelyi, who is close to Hung...

Galenica AB

Rickard Sandberg on this year’s Nobel Prize in Medicine: ”A key discovery”

The discovery that paved the way for the development of todays mRNA vaccines is the basis for this year’s Nobel Prize in Physiology or Medicine.

600 million SEK for life science - "Should not be the country of moderation"

Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.

About Microscope Ergonomics

Learn about ergonomic microscope design and how you can increase your well-being and productivity when working in clinical microscopy. Read about challenges, de...

“A major energy boost for the entire cancer vaccine field”

The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...

Forskning kring immunterapier mot cancer belönas med Sjöbergpriset

Årets Sjöbergpris på en miljon dollar går till den amerikanska forskaren Miriam Merad för hennes forskning kring kroppens egen förmåga att bekämpa cancertumörer.

Quotient Sciences Limited

Your solution for right part positioning

ZEISS OmniFix CT - right part positioning solution to get meaningful measuring results for all part sizes.